Cutaneous side effects in 19 lung cancer patients treated with Gefitinib (Iressa®)

Nishinihon Journal of Dermatology

Volumn 66, Issue 6, 2004, Pages 602-607

  Uchihira, Miho ^a   Ejima, Takahiro ^a   Uchihira, Takao ^a   Araki, Jun ^a   Kamei, Toshiaki ^a  

^a Yamaguchi Pref Central Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GEFITINIB;

ACNE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HUMAN; INTERSTITIAL PNEUMONIA; LIVER DYSFUNCTION; LUNG CANCER; LUNG DISEASE; LUNG NON SMALL CELL CANCER; MALE; PARONYCHIA; SEBORRHEIC DERMATITIS; SKIN MANIFESTATION; TREATMENT OUTCOME; XEROSIS;

EID: 11144337316     PISSN: 03869784     EISSN: None     Source Type: Journal    
DOI: 10.2336/nishinihonhifu.66.602     Document Type: Article

References (9)

1. Baselga J et al: Phase I safty, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20: 4292-4302, 2002.
2. Doom RV et al: Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 147: 598-601, 2002.
3. Nanney LB et al: Comparison of epidermal growth factor binding and receptor distribution in normal human epidermal appendages. J Invest Dermatol 83: 385-393, 1984.
4. Bunsam KJ et al: Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor anti-body C225. Br J Dermatol 144: 1169-1186, 2001.
5. Albanell J et al: Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients, histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20: 110-124, 2002.
6. Kimyai-Asadi A, Jih MH: Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors. Arch Dermatol 138: 129-131, 2002.
7. Roman Perez-Soler et al: Final results a phase II study of erlotinib (Tarceva™) monotherapy in patients with advanced non-small cell lung cancer following failure of platinum-based chemotherapy. Lung Cancer 41: 246, 2003.
8. Clark GM et al: Rash severity is predictive of increased survival with erlotinib HCL. J Clin Oncol 22: 196, 2003.